Amol Akhade: Shining light on real-world HER2+ breast cancer care
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn about a paper by Sudeep Gupta et al. published in JCO Global Oncology:
“Congratulations to Dr. Sudeep Gupta, Sir, and the Breast DMG team at TMH for their impactful publication in JCO Global Oncology!
A proud moment for Indian oncology – shining light on real-world HER2+ breast cancer care.
Study Snapshot
- Tata Memorial Centre, 2014–2018
- 1,004 patients with non-metastatic HER2-positive breast cancer received neoadjuvant therapy (NAT)
Key Findings
- pCR achieved in 22.5%
- 5-year EFS: 86.1% (vs. 57% in no-pCR)
- 5-year OS: 87.3% (vs. 64.7% in no-pCR)
Predictors of pCR:
- Smaller tumors (cT1/2)
- Higher grade (Grade III)
- Hormone receptor–negative
Trastuzumab use
- Trastuzumab Access and Impact
- Only 70.8% received trastuzumab
- >24 weeks: OS 80.5%, EFS 77.3%
- ≤24 weeks: OS 69.5%, EFS 63.4%
- None: OS 58.9%, EFS 50.1%
Trastuzumab was an independent predictor of survival (HR ~0.60, P < .001)
Prognostic Value of Tumor Burden
Even after pCR, baseline burden mattered:
- Tumor size: OS 83.9% (cT3/4) vs. 90.9% (cT1/2)
- Nodal status: OS 84.1% (cN2/3) vs. 90.0% (cN0/1)
Toxicity Profile
Grade ≥3 AEs: 8.4%
Conclusion
Early diagnosis and prolonged trastuzumab are crucial.
Baseline tumor burden remains prognostic, even in pCR achievers.”
Authors: Minit Shah, Sushmita Rath, Seema Gulia, Prabhat Bhargava, Anbarasan Sekar, Ankush Shetake, Manali Kolkur, Shalaka Joshi, Rajendra Badwe, Sudeep Gupta et al.
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023